Company Overview: Onconova

Industry News

5 Sep

Onconova Therapeutics to Participate in Two Investor Conferences in September

NEWTOWN, Pa., Sept. 05, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that they will present at the Rodman & Renshaw 19th Annual Global Investment Conference...

Read more

25 Jul

Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”

Company to highlight approaches for studying rigosertib in multiple rare diseases associated with RAS gene at upcoming scientific conference Collaboration with National Cancer Institute (NCI) for evaluation of rigosertib in pediatric rare disease Onconova to host KOL breakfast symposium for investors on October 11th, 2017 NEWTOWN, Pa., July 25,...

Read more

26 Jun

Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid

Oral Rigosertib combined with Azacitidine administered to patients with treatment naïve and refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes, demonstrates responses in difficult-to-treat population •  The combination may overcome hypomethylating agent resistance; further study in Acute Myeloid Leukemia is warranted Nonclinical study of Rigosertib combined with Azacitidine suggests epigenetic...

Read more

13 Jun

Onconova Therapeutics to Present at the BIO International Convention

NEWTOWN, Pa., June 13, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that Dr. Ramesh Kumar, President & CEO, will...

Read more

5 Jun

Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting

NEWTOWN, Pa., June 05, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced the results of a Phase 2 study with...

Read more

15 May

Investor Network: Onconova Therapeutics Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 15, 2017 / Onconova Therapeutics Inc. (NASDAQ: ONTX) will be discussing their earnings results in their Q1 Earnings Call to be held 5/15/2017 at 9:00 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/22398. Replay Information The replay will...

Read more

Page 1 of 612345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address